

EXECUTIVE SUMMARY FOR STAKEHOLDERS

Maxilin is a high-potency **synbiotic / eubiotic** formulation containing *Lactobacillus acidophilus* strain N 2585. Designed to restore microflora homeostasis, Maxilin exhibits targeted antagonistic activity against virulent opportunistic pathogens, demonstrating its **highest level of growth suppression against *Candida albicans***.

Unlike standard dietary supplements, Maxilin acts as an active eubiotic agent that suppresses opportunistic fungal yeast (*Candida*) and pathogenic bacteria while restoring a balanced internal microflora environment.

LABORATORY & VISUAL PROOF

In Vitro Culture Assay Findings

Direct laboratory testing confirms that Maxilin's active strain restricts *Candida albicans* growth through organic acid production and antimicrobial metabolites.

- **Targeted Growth Suppression:** Suppresses *Candida albicans* more actively than major bacterial pathogens.
- **Biofilm & Acidity Control:** Lowers microenvironment pH, creating unfavorable conditions for fungal germination.
- **Rapid Action:** Clinical and laboratory data indicate significant pathogen reduction within **3 to 4 days**.



- Visual Guide:**
- **Row 1 (Control):** Smooth liquid = active fungal growth.
 - **Row 2 (Maxilin):** Specks/dots = Maxilin clumped, neutralized, and stopped the fungus.

CLINICAL STUDY EFFICACY PROFILE

Target Microorganism	Inhibitory Power	Effect on Pathogen Growth	Clinical / Synbiotic Relevance
<i>Candida albicans</i> (Fungus)	Highest	Direct Growth Suppression	Prevents fungal dysbiosis & yeast overgrowth
<i>Pseudomonas aeruginosa</i>	High	Reverses Resistance	Eradicates opportunistic wound infections
<i>Staphylococcus aureus</i>	Moderate–High	Reverses Resistance	Mitigates inflammatory complications
<i>Escherichia coli</i>	Moderate	Reverses Resistance	Normalizes enteric microflora balance

SOURCE REFERENCES & WEB LINKS

- PubMed Clinical Study (PMID 10961107): <https://pubmed.ncbi.nlm.nih.gov/10961107/>
- |
- |